Publications by authors named "Edward Reilly"

Claim this Profile
A
ABBV-303 is a Natural Killer Cell Engager Specific for c-Met-Expressing Tumors.
Jennifer D Stone, Kamonwan Fish, Devika Ashok, Laura M McKay, Saeed S Akhand, Edward B Reilly

Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma.
Durga B Dandamudi, Iwona M Konieczna, Kelly M Calabrese, Monica Wielgos-Bonvallet, Christiaan Kweekel, Edward B Reilly

Leuk Lymphoma· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DRUG AND SINGLE-CELL GENE EXPRESSION INTEGRATION IDENTIFIES SENSITIVE AND RESISTANT GLIOBLASTOMA CELL POPULATIONS.
Robert K Suter, Anna M Jermakowicz, Rithvik Veeramachaneni, Matthew D'Antuono, Longwei Zhang, Edward B Reilly

bioRxiv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiolabeling and Preclinical Evaluation of Therapeutic Efficacy of Ac-ch806 in Glioblastoma and Colorectal Cancer Xenograft Models.
Christian W Wichmann, Katherine A Morgan, Zhipeng Cao, Laura D Osellame, Nancy Guo, Edward Reilly

J Nucl Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models.
Sonia Jain, Jessica I Griffith, Kendra A Porath, Sneha Rathi, Jiayan Le, Edward B Reilly

Clin Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.
Maissa Mhibik, Erika M Gaglione, David Eik, John Herrick, Janet Le, Edward B Reilly

Blood Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.
Adam S Chervin, Jennifer D Stone, Iwona Konieczna, Kelly M Calabrese, Ningyan Wang, Edward B Reilly

Mol Cancer Ther· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.
Benedito A Carneiro, Kyriakos P Papadopoulos, John H Strickler, Andrew B Lassman, Saiama N Waqar, Edward B Reilly

Neurooncol Adv· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts.
Kendra A Porath, Michael S Regan, Jessica I Griffith, Sonia Jain, Sylwia A Stopka, Edward B Reilly

Neurooncol Adv· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biodistribution Analysis of an Anti-EGFR Antibody in the Rat Brain: Validation of CSF Microcirculation as a Viable Pathway to Circumvent the Blood-Brain Barrier for Drug Delivery.
Ghazal Naseri Kouzehgarani, Pankaj Kumar, Susan E Bolin, Edward B Reilly, Didier R Lefebvre

Pharmaceutics· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A vision for integrated publicly available information on regulated medical products.
Khyati Roberts, Roopal Thakkar, Lina Aljuburi, Donna Boyce, Sean Curtis, Edward Reilly

Clin Transl Sci· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19: A Catalyst to Accelerate Global Regulatory Transformation.
Jerry Stewart, Peter Honig, Lina AlJuburi, Deborah Autor, Susan Berger, Edward Reilly

Clin Pharmacol Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 and Biodistribution Study of ABT-806i, an In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
Hui K Gan, Matthew Burge, Benjamin Solomon, Sze Ting Lee, Kyle D Holen, Edward B Reilly

J Nucl Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition.
Mark G Anderson, Qian Zhang, Luis E Rodriguez, Claudie M Hecquet, Cherrie K Donawho, Edward B Reilly

BMC Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.
Kedar S Vaidya, Michael J Mitten, Adelyn L Zelaya-Lazo, Anatol Oleksijew, Cory Alvey, Edward B Reilly

J Neurooncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Creating E-Labeling Platforms: An Industry Vision.
Khyati Roberts, Roopal Thakkar, Deborah Autor, Fabio Bisordi, Helen Fitton, Edward Reilly

Clin Pharmacol Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate.
Mark G Anderson, Hugh D Falls, Michael J Mitten, Anatol Oleksijew, Kedar S Vaidya, Edward B Reilly

Mol Cancer Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma.
Puey-Ling Chia, Sagun Parakh, Ming-Sound Tsao, Nhu-An Pham, Hui K Gan, Edward B Reilly

Pharmaceuticals (Basel)· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors.
John H Strickler, Patricia LoRusso, Ravi Salgia, Yoon-Koo Kang, Chia Jui Yen, Edward Reilly

Mol Cancer Ther· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
John H Strickler, Colin D Weekes, John Nemunaitis, Ramesh K Ramanathan, Rebecca S Heist, Edward B Reilly

J Clin Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor.
Kedar S Vaidya, Anatol Oleksijew, Lora A Tucker, William N Pappano, Mark G Anderson, Edward B Reilly

Pharmacology· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Glenwood D Goss, Everett E Vokes, Michael S Gordon, Leena Gandhi, Kyriakos P Papadopoulos, Edward B Reilly

Cancer· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
Andrew C Phillips, Erwin R Boghaert, Kedar S Vaidya, Hugh D Falls, Michael J Mitten, Edward B Reilly

Mol Cancer Ther· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both -Amplified and c-Met-Overexpressing Tumors, Irrespective of Pathway Dependence.
Jieyi Wang, Mark G Anderson, Anatol Oleksijew, Kedar S Vaidya, Erwin R Boghaert, Edward B Reilly

Clin Cancer Res· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Data acquisition variability using profilometry to produce accurate mean total volumetric wear and mean maximum wear depth measurements for the OHSU oral wear simulator.
Garry J P Fleming, Edward Reilly, Adam H Dowling, Owen Addison

Dent Mater· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis